Feature | March 24, 2014

New Treatment for Atrial Fibrillation Reduces Stroke Risk

Lariat device seals the left atrial appendage

atrial fibrillation, LARIAT
March 24, 2014 – Doctors at the Stony Brook Heart Institute Electrophysiology Lab are using a new nonsurgical technique called the Lariat Suture Delivery Device to treat patients with atrial fibrillation (AF) who cannot tolerate blood-thinning medication.
AF is the most common heart rhythm disorder that causes the upper chambers of the heart to beat fast and erratically. An estimated 2.7 million Americans are living with the disorder, and if uncontrolled, it can have serious consequences, including stroke and early death. Currently, the condition accounts for more than 20 percent of stroke-related deaths.
Patients are normally given blood thinners such as warfarin and other anticoagulants to manage their condition by preventing blood clots. However, patients must rigorously manage the level of the drugs in their blood. For most patients, these blood thinners are very effective in reducing the risk of stroke, but there is a potential for bleeding, which in some cases can be serious. For those individuals who cannot tolerate blood thinners due to prior bleeding or who are at a high risk for bleeding, the Lariat procedure can safely reduce the risk of stroke without any further bleeding risk.
The Lariat procedure is a nonsurgical, minimally-invasive technique that uses sutures to tie off the left atrial appendage (LAA) of the heart. This area of the heart is the primary source of blood clots leading to stroke in patients with atrial fibrillation.
With the patient under general anesthesia, physicians guide two catheters into the patient’s heart to seal the LAA with a pre-tied suture loop — similar to a lasso — with the Lariat device. Rather than a surgical procedure, the technique uses a needle to introduce catheters into the heart.
“In the past there weren’t any alternatives that we could really offer these types of patients,” said Roger Fan, M.D., associate professor, department of medicine, director of arrhythmia consult service. “The Lariat is a great alternative to the possibility of a lifetime of blood thinners, which can have some serious side effects like GI bleeds, as well as an alternative to invasive open-heart surgery.” 
On Dec. 3, 2013, Fan and his team at the Stony Brook Heart Institute completed their first Lariat procedure without having to spread the ribcage or cut through bone to reach the heart.
For more information, visit www.heart.stonybrookmedicine.edu

Related Content

UAB, University of Alabama at Birmingham study, stroke prevention, non-valvular atrial fibrillation, NVAF
News | Atrial Fibrillation| October 25, 2016
A recent study from University of Alabama at Birmingham (UAB) researchers published in PLOS ONE compares different...
Medtronic, FIRE AND ICE trial, Arctic Front, cryoballoon catheter ablation, radiofrequency RF ablation, study results, Asia Pacific Heart Rhythm Society Scientific Sessions
News | Ablation Systems| October 17, 2016
Medtronic plc last week unveiled new health economic analysis data from the FIRE AND ICE trial that favor cryoballoon...
SentreHeart, Eclipse Surgical Device, left atrial appendage, LAA closure, first clinical use, Poland
News | Left Atrial Appendage (LAA) Occluders| October 13, 2016
SentreHeart Inc. announced this week it has treated the first patients using the Eclipse Surgical Device, which is...
CardioKinetix, Parachute device, Heart Failure device therapy

The CardioKinetix Parachute device implant shown deployed in the left ventricle of a heart failure patient. The device helps remodel the ventricle to improve the heart's ability to pump blood more efficiently. 

Feature | Heart Failure| September 29, 2016 | Abha Mishra
New cardiovascular device therapies for atrial fibrillation (AF) and heart failure (HF) are rapidly evolving with the
European Heart Rhythm Association, EHRA White Book 2016, EP Europace supplement, cardiac rhythm device use, Europe
News | EP Lab| September 27, 2016
In August, the European Heart Rhythm Association (EHRA) and EP Europace journal announced the release of the supplement...
St. Jude Medical, Amplatzer Amulet LAA occluder, left atrial appendage, IDE trial
News | Left Atrial Appendage (LAA) Occluders| September 02, 2016
St. Jude Medical Inc. announced the start of the St. Jude Medical Amplatzer Amulet IDE trial of the company’s Amplatzer...
Pradaxa, dabigatran, GLORIA-AF registry, ESC Congress 2016, NVAF
News | Antiplatelet and Anticoagulation Therapies| September 01, 2016
First outcome results from the GLORIA-AF Registry show that treatment with Pradaxa (dabigatran etexilate mesylate) was...
News | Cardiac Resynchronization Therapy Devices (CRT)| August 30, 2016
August 30, 2016 — Medtronic plc announced results from the...
Merlin, Merlin@home, SJM, St. Jude Medical Merlin, cybersecurity

St. Jude Medical said recent claims of the cyber attack vulnerability of its [email protected] remote monitoring system and its implantable EP devices are not true.

Feature | EP Lab| August 29, 2016 | Dave Fornell
August 29, 2016 — Investment research firm Muddy Waters Capital released a report Aug. 25 saying it believes St.
Overlay Init